Capital World Investors Sells 1,519,407 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Capital World Investors cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 35.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,778,980 shares of the biopharmaceutical company's stock after selling 1,519,407 shares during the quarter. Capital World Investors owned 2.53% of Regeneron Pharmaceuticals worth $1,979,491,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Capital International Investors raised its position in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after buying an additional 155,369 shares during the period. Dodge & Cox increased its position in shares of Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after acquiring an additional 9,381 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 7.9% during the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after acquiring an additional 149,124 shares during the period. Finally, Loomis Sayles & Co. L P raised its holdings in shares of Regeneron Pharmaceuticals by 33.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after acquiring an additional 393,997 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded up $2.36 during mid-day trading on Wednesday, reaching $587.85. 730,926 shares of the company were exchanged, compared to its average volume of 716,898. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a market cap of $64.27 billion, a PE ratio of 15.36, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20. The company has a fifty day moving average of $642.12 and a 200 day moving average of $732.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $11.86 EPS. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.60%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Wall Street Analyst Weigh In

Several research firms have weighed in on REGN. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday. They set an "overweight" rating and a $695.00 price objective on the stock. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research note on Monday, March 31st. Bernstein Bank decreased their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. The Goldman Sachs Group cut their price target on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Finally, Robert W. Baird decreased their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $949.60.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.